A pill being developed to treat postpartum depression is showing promise for new parents who suffer from the condition, according to newly released clinical trial data.
The study, published Wednesday in The American Journal of Psychiatry, found the drug, zuranolone, from makers Sage Therapeutics and partner company Biogen, demonstrated “significant improvements in depressive symptoms and was generally well tolerated.”
The late stage, double-blind trial analyzed nearly 200 patients with severe postpartum depression who were given either 50 milligrams per day of zuranolone or a placebo for 14 days.
“Treatment with zuranolone compared with placebo resulted in statistically significant improvements in symptoms at day 15,” the researchers reported.
The most common adverse effects reported with the drug were somnolence (drowsiness), dizziness and sedation. “No loss of consciousness, withdrawal symptoms, or increased suicidal ideation or behavior were observed,” the study authors wrote.
vCard.red is a free platform for creating a mobile-friendly digital business cards. You can easily create a vCard and generate a QR code for it, allowing others to scan and save your contact details instantly.
The platform allows you to display contact information, social media links, services, and products all in one shareable link. Optional features include appointment scheduling, WhatsApp-based storefronts, media galleries, and custom design options.
Zuranolone is designed to be taken as a once-a-day pill for 14 days. It is not yet approved by the Food and Drug Administration, but the agency is expected to make a decision on it in early August.
If approved, it could offer a new option for some of the estimated 1 in 8 women who experience symptoms of postpartum depression, which can include sadness, anxiety, irritability, loss of appetite and even self-harm.
Currently, there is only one drug on the market specifically designed to treat postpartum depression: Zulresso, developed by Sage. That drug, launched in 2019, is given intravenously to patients for 60 hours in a health care setting.
A 14-day, fast-acting daily pill option, if approved, could make treatment more accessible.
“Of course, we think that zuranolone will be accessible to many, many more patients and we’re excited by that, to really fulfill that unmet need,” Amy Schacterle, Sage’s senior vice president of research and development strategy, recently told CBS News Boston.
-Louisa Moller contributed to this report.
Amazon looking to expand AI use in homes using Alexa
Soldiers in Niger announce coup as guards take president hostage
Federal grand jury reconvenes in Jan. 6 investigation, which could lead to Trump indictment